Microneedle-based delivery of cell membrane vesicles as IL-17RA decoys for Psoriasis treatment - PubMed
2 days ago
- #Psoriasis
- #IL-17RA
- #Microneedles
- Microneedle-based delivery of cell membrane vesicles (IL-17RA-CMVs) as decoy receptors for psoriasis treatment.
- IL-17RA-CMVs block IL-17/IL-17RA signaling, offering broad-spectrum neutralization of IL-17 ligands.
- Engineered 293T cells with high IL-17RA expression used to produce IL-17RA-CMVs.
- IL-17RA-CMVs loaded into hyaluronic acid microneedles (MNs) for efficient skin penetration and rapid dissolution.
- Topical application of mIL-17RA-CMVs-MNs significantly reduced psoriasis severity in an IMQ-induced mouse model.
- Treatment downregulated inflammatory mediators (CXCL1, CXCL2, CCL20) and antimicrobial peptides (S100A7/A8/A9).
- hIL-17RA-CMVs neutralized IL-17A in vitro, inhibiting pro-inflammatory cytokines and keratinocyte hyperproliferation.
- Combines decoy receptor vesicles with microneedles for localized, minimally invasive therapy.
- Potential application for psoriasis and other IL-17-mediated inflammatory diseases.